Ulcerative Colitis Clinical Trial
— VIRTUOSOOfficial title:
A Comparison Of High Definition White Light And High Definition Virtual Chromoendoscopy For The Detection Of Intraepithelial Neoplasia In Longstanding Colitis: A Randomised Controlled Trial
NCT number | NCT02822352 |
Other study ID # | PHT/2016/02 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2016 |
Est. completion date | August 7, 2018 |
Verified date | January 2019 |
Source | Portsmouth Hospitals NHS Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Colitis is inflammation of the large bowel and it is often caused by conditions known as
ulcerative colitis and Crohn's disease. In these conditions, the body has an exaggerated
inflammatory response against the bowel - the body attacks the bowel. Patients who have had
colitis affecting most of the large bowel for more than 8 years are at increased risk of
cancer of the large bowel. In view of this, many national gastroenterology organisations have
recommended that such patients have regular colonoscopies to detect pre-cancerous areas and
even early cancer in the large bowel. Early detection of such areas, will lead to early
treatment thereby reducing the risk of developing significant large bowel cancer. These
regular colonoscopies are known as surveillance colonoscopies.
Official international guidelines for surveillance in patients with ulcerative and Crohn's
colitis advise to take 4 random samples of large bowel tissue (biopsies) every 10 centimeters
and of any suspicious areas. Recent studies have shown that spraying dye such as indigo
carmine (a type of food dye) helps highlight abnormal areas that could harbor pre-cancerous
cells. This technique is time-consuming, and tedious. There are no set standards of what is
considered a satisfactorily completed dye spray colonoscopy. The uptake of this technique in
the UK has not been uniform. Therefore virtual chromoendoscopy has been studied as an
alternative method to improve the detection of pre-cancerous tissue in patients with
longstanding colitis.
Status | Completed |
Enrollment | 204 |
Est. completion date | August 7, 2018 |
Est. primary completion date | March 8, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Ulcerative Colitis or Crohn's colitis with a disease duration of >8 years for pancolitis or >15 years duration for left-sided colitis - Aged 18 years and above - Patients able to give informed consent Exclusion Criteria: - Persistent coagulopathy or platelet count <50x1012 which may preclude mucosal biopsy - Known colonic IN or CRC - Fulminant colitis - Patients who have been previously randomised and withdrawn on 2 occasions due to poor bowel preparation - Patients who are pregnant |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Portsmouth Hospitals NHS trust | Portsmouth | Hampshire |
Lead Sponsor | Collaborator |
---|---|
Portsmouth Hospitals NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To compare the rates of neoplasia detection using virtual chromoendoscopy compared to high definition white light (HDWL) endoscopy | 14 months | ||
Secondary | To assess the neoplasia detection rate in targeted biopsies versus non-targeted (segmental) biopsies within each arm of the study | The above is assessed by comparing the mean neoplasia per patient detection rate between virtual chromoendoscopy and high definition white light endoscopy as well as by assessing the yield of non-targeted quadratic biopsies in detecting neoplasia | 14 months | |
Secondary | To compare the duration of time taken using each technique | This is measured by assessing the total withdrawal time taken in each arm of the study | 14 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |